Inhalation Sciences Sweden Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Manoush Masarrat

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Dec 29

CEO

Manoush Masarrat (46 yo)

4.6yrs

Görev süresi

Mr. Manoush Masarrat has been Chief Executive Officer at Inhalation Sciences Sweden AB (publ) since September 16 2019. Mr. Masarrat had served as Director of Inhalation Sciences Sweden AB (publ) since Dece...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Per Gerde	Chief Scientific Officer & Director	no data	Veri yok	5.08% SEK 3.3m
Per Wollmer	Member of Advisory Board	no data	Veri yok	Veri yok
Daniel Spasic	Chairman of the Board	3.9yrs	Veri yok	Veri yok
Jan Hellqvist	Director	1.6yrs	Veri yok	Veri yok
Sonja Gerde	Director	5.9yrs	Veri yok	Veri yok
Gary Pitcairn	Member of Advisory Board	no data	Veri yok	Veri yok
Martin Wehling	Member of Advisory Board	no data	Veri yok	Veri yok
Magnus Svartengren	Member of Advisory Board	no data	Veri yok	Veri yok
Carsten Ehrhardt	Member of Advisory Board	no data	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ISAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Inhalation Sciences Sweden Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

No independent directors

Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors

No independent directors

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022

Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales

Recent updates

Inhalation Sciences Sweden AB (publ) to Report Nine Months, 2024 Results on Nov 20, 2024

Inhalation Sciences Sweden AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022)

New major risk - Share price stability

Inhalation Sciences Sweden AB (publ) to Report Q3, 2023 Results on Nov 22, 2023

New major risk - Revenue and earnings growth

Inhalation Sciences Sweden AB (publ) to Report Q2, 2023 Results on Aug 29, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.20 loss per share (vs kr0.30 loss in 1Q 2022)

Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.31 loss per share (vs kr0.40 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: kr0.36 loss per share (vs kr0.56 loss in 2Q 2021)

Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors

Inhalation Sciences Receives Landmark FDA Approval for Co-Financing of its Study to Validate Dissolvit as a Standard Research Method in the US

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Inhalation Sciences Submits Whitepaper to FDA Aiming to Establish DissolvIt® as an FDA-Recommended Standard Research Method in US

Inhalation Sciences Announces Positive Study Results

Second quarter 2021 earnings released: kr0.56 loss per share (vs kr1.92 profit in 2Q 2020)

Investor sentiment improved over the past week

Inhalation Sciences Completes Enrolment in PreciseInhale Clinical Trial

Inhalation Sciences Sweden AB (Publ) Receives CTA Approval for Landmark Clinical Trial of Preciseinhale

Investor sentiment improved over the past week

First quarter 2021 earnings released: kr0.40 loss per share (vs kr0.068 profit in 1Q 2020)

Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021

New 90-day low: kr10.30

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales

Market bids up stock over the past week

Inhalation Sciences Receives New Order Worth EUR 196,000 from University of Vienna

New 90-day low: kr10.80

Inhalation Sciences Announces to Successfully Installed its First Ever Commercial Version of the in Vitro Dissolvit Module at the Swiss Laboratory of a Long-Term ISAB Customer

An undisclosed buyer acquired an unknown stake in Ziccum AB (publ) (NGM:ZICC) from Inhalation Sciences Sweden AB (publ) (NGM:ISAB) for approximately SEK 21.2 million.

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş